

The colorectal carcinoma – treatment research and treatment reality in oncology practices

A.-R. Valdix¹, S. Zaun², R. Göttel³, HW. Tessen⁴, Project team of Internal Oncology (PIO)

¹Specialized oncology practice Schwerin, ²Sanofi-Aventis Deutschland GmbH, ³rgb Onkologisches Management GmbH Sarstedt, ⁴Specialized oncology practice Goslar

Introduction

Which contribution does a continuous, systematic case documentation and evaluation provide to treatment research? What is the significance of new substances such as Aflibercept?

Methods

Data from oncology practices from 2003-2015 (PIO, ONCOReg).

7,802 histories of diseases comprising 12,623 palliative treatments originating from 123 oncology practices from 16 federal states are available for analysis. 12,446 treatments have been concluded so far and a response has been recorded in 11,655 of them.

Results

Patient characteristics

Gender: m: 60%, f: 40%

Distant metastatic diseases: 5,151 patients (85% lung/liver)

KRAS mutation status (n = 1,957): 63% wild type, 37% mutant

Median age at start of 1st-line therapy: 68 (19-92) years

Palliative chemotherapy (n = 5,076):

Therapy	%
1 st -line	100
2 nd -line	68
3 rd -line	37
4 th -line	18

Median duration of treatment (n = 11,446): 119 d

Response (n = 11,655):

%	OR	NC	PD	unkn.
overall	28	38	23	11
1st-line	41	37	12	10
2nd-line	23	41	26	10
3rd-line	16	37	34	13
4th-line	11	35	40	14

Survival

PFS/OS as of start of 1st-line treatment: 9.5/24.7 mths.

PFS/OS as of start of 2nd-line treatment: 6.4/15.1 mths.

27 practices treated 98 patients with **aflibercept** (87% with FOLFIRI).

Median age at start of 1st-line treatment: 74 years.

3% of patients received a 1st-line Ctx, 32% 2nd-line, 22% 3rd-line, 20% 4th-line, 12% 5th-line, 10% 6-8th-line.

97% of patients had been pretreated with oxaliplatin (24%) adjuvant, 81% palliativ), 71% with bevacizumab, 27% with cetuximab, 16% with panitumumab.

Median duration of aflibercept-based therapy (n = 65): 73

Response

%	OR	NC	PD	unkn.
overall (n = 67)	10	28	39	22
1st-line (n = 3)	33	33	0	33
2nd-line (n = 21)	9	38	48	5
3rd-line (n = 10)	20	20	40	20
4th-line (n = 17)	13	29	29	29

Conclusions:

The data collected over a long period of time depict very precisely the reality of treatment in oncology practices in Germany. The analysis presented provides an important contribution to the complex of treatment research and answers a series of patient-related questions.

Aflibercept is applied according to its approved use. Current data will be presented.